Cellectis S.A.
CLLS
NASDAQ·Healthcare·Biotechnology·Mkt cap $325.4M
$3.24
▼ -2.41%
P/E
-4.88
Mkt Cap
$325.4M
52-Wk Range
$2.35–$5.48
52-Week Range
$2.35 - $5.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.9). Larger-than-normal price swings expected.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+10.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CLLS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.22 vs -$0.26 consensus (+16.4% surprise). Revenue of $12.5M vs $11.0M expected (+13.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.4%
Revenue trend · last 8Q
—
—
—
—
+117%
-18%
-46%
-69%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.2M
$12.7M
$10.7M
$16.7M
$35.2M
$10.4M
$5.8M
$5.2M
Margins · last 8Q
Profit
-417.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · $9.00 · May 28, 2026
vs Industry
How CLLS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.